Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Colomer

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Cancers|June 24, 2022
Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLCJacobo Rogado, Fernando Pozo, Kevin Troule, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 23, 2022
Excess weight and anti-PD-1 immune checkpoint inhibitor's outcomes in non-small cell lung cancerJacobo Rogado, Fernando Pozo, Kevin Troulé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinomaRamon Colomer, Mariano Monzo, Ignasi Tusquets, et al.
Nature Communications|November 3, 2019
Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cellsMaria J Bueno, Veronica Jimenez-Renard, Sara Samino, et al.
Cancers|June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast CancerChau Dang, Michael S Ewer, Suzette Delaloge, et al.
The Lancet. Oncology|December 28, 2020
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 studyAntoinette R Tan, Seock-Ah Im, André Mattar, et al.
JAMA Oncology|April 15, 2016
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical TrialAhmad Awada, Ramon Colomer, Kenichi Inoue, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 26, 2011
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinomaCarlos Gómez-Martín, Angel Concha, José María Corominas, et al.
Frontiers in Psychology|November 22, 2021
Emotional Distress in Cancer Patients During the First Wave of the COVID-19 PandemicPatricia Toquero, Carmen Blanco Fernández, María Pilar López Martí, et al.
Oncoimmunology|May 5, 2020
Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodiesJacobo Rogado, Nuria Romero-Laorden, José Miguel Sanchez-Torres, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Cancers|June 24, 2022
Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLCJacobo Rogado, Fernando Pozo, Kevin Troule, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 23, 2022
Excess weight and anti-PD-1 immune checkpoint inhibitor's outcomes in non-small cell lung cancerJacobo Rogado, Fernando Pozo, Kevin Troulé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinomaRamon Colomer, Mariano Monzo, Ignasi Tusquets, et al.
Nature Communications|November 3, 2019
Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cellsMaria J Bueno, Veronica Jimenez-Renard, Sara Samino, et al.
Cancers|June 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast CancerChau Dang, Michael S Ewer, Suzette Delaloge, et al.
The Lancet. Oncology|December 28, 2020
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 studyAntoinette R Tan, Seock-Ah Im, André Mattar, et al.
JAMA Oncology|April 15, 2016
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical TrialAhmad Awada, Ramon Colomer, Kenichi Inoue, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 26, 2011
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinomaCarlos Gómez-Martín, Angel Concha, José María Corominas, et al.
Frontiers in Psychology|November 22, 2021
Emotional Distress in Cancer Patients During the First Wave of the COVID-19 PandemicPatricia Toquero, Carmen Blanco Fernández, María Pilar López Martí, et al.
Oncoimmunology|May 5, 2020
Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodiesJacobo Rogado, Nuria Romero-Laorden, José Miguel Sanchez-Torres, et al.
Pageof 8